<DOC>
	<DOCNO>NCT01021748</DOCNO>
	<brief_summary>This study investigate safety tolerability combination therapy MK-2206 AZD6244 determine maximum tolerate dose ( MTD ) recommend Phase 2 dose ( RPTD ) drug combination treatment participant locally advance metastatic solid tumor . Preliminary efficacy data also collect .</brief_summary>
	<brief_title>A Combination Therapy Study MK-2206 AZD6244 Participants With Advanced Solid Tumors ( MK-2206-010 )</brief_title>
	<detailed_description />
	<criteria>Participant confirm metastatic locally advanced solid tumor fail respond standard therapy , progress despite standard therapy , therapy know provide clinical benefit , efficacious standard therapy therapy know provide clinical benefit exist Participant history prior cancer , except certain cervical , skin , prostate cancer , undergone potentially curative therapy evidence disease 5 year At least 18 year age Participant able swallow oral medication For participant enrol MTD expansion cohort , must diagnosis Kirsten rat sarcoma viral oncogene homolog ( KRAS ) tumortype non smallcell lung cancer ( NSCLC ) . Additional tumor type ( specific mutation ) may add MTD expansion cohort discussion Sponsor Investigator Participant chemotherapy , radiotherapy biological therapy within 4 week enter study Participant currently participate participate study investigational compound device within 30 day 5x compound 's halflife Cycle 1 , Day 1 Participant known central nervous system metastases and/or carcinomatous meningitis Participant primary central nervous system tumor spinal cord compression Participant , time signing informed consent , regular user ( include `` recreational use '' ) illicit drug recent history ( within last year ) drug alcohol abuse Participant pregnant breastfeeding expect conceive father child within project duration study Participant human immunodeficiency virus ( HIV ) positive Participant history hepatitis B C active hepatitis A Participant history current evidence heart disease Participant uncontrolled high blood pressure Participant poorly control diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>